



Press Release dated April 19, 2012

Contact: **Trinity Biotech plc**  
Kevin Tansley  
(353)-1-2769800  
E-mail: [kevin.tansley@trinitybiotech.com](mailto:kevin.tansley@trinitybiotech.com)

**Lytham Partners LLC**  
Joe Diaz, Joe Dorame & Robert Blum  
602-889-9700

## **Trinity Biotech Announces Quarter 1 Financial Results EPS of 19.4 cents per ADR – an increase of 11%.**

**DUBLIN, Ireland (April 19, 2012)**.... Trinity Biotech plc (Nasdaq: TRIB), a leading developer and manufacturer of diagnostic products for the point-of-care and clinical laboratory markets, today announced results for the quarter ended March 31, 2012.

### ***Quarter 1 Results***

Total revenues for Q1, 2012 were \$20.0m which compares to \$18.7m in Q1, 2011, an increase of 7.4%.

Point-Of-Care revenues for Q1, 2012 increased by 13.3% when compared to Q1, 2011. This increase was mainly attributable to increased HIV sales in Africa.

Clinical Laboratory revenues increased from \$14.1m to \$14.9m, which represents an increase of 5.5% compared to Q1, 2011. This included increased revenues from sales of the new Premier instrument, including the first placements in the USA.

Revenues for Q1, 2012 by key product area were as follows:

|                     | <b>2011<br/>Quarter 1</b> | <b>2012<br/>Quarter 1</b> | <b>Increase</b> |
|---------------------|---------------------------|---------------------------|-----------------|
|                     | <b>US\$'000</b>           | <b>US\$'000</b>           | <b>%</b>        |
| Point-of-Care       | 4,521                     | 5,121                     | 13.3%           |
| Clinical Laboratory | 14,133                    | 14,905                    | 5.5%            |
| <b>Total</b>        | <b>18,654</b>             | <b>20,026</b>             | <b>7.4%</b>     |

Gross profit for Q1, 2012 amounted to \$10.3m representing a gross margin of 51.6% which represents an improvement from the 51.2% for the same period in 2011. This improvement was due to increased Point-Of-Care sales, which traditionally have higher gross margins. However, this was partially offset by lower margins on increased sales of Premier instruments.

Research and Development expenses increased from \$0.7m to \$0.8m, representing an increase of 23%. Meanwhile Selling, General and Administrative (SG&A) expenses increased from \$5.0m to \$5.2m compared to Q1, 2011. This was mainly due to professional fees related to the acquisition of Fiom Diagnostics AB during the quarter.

Operating Profit increased from \$3.7m to over \$4.1m for Q1, 2012 which was an increase of 11.7%. In the same period operating margin increased from 19.8% to 20.6%.

Net financial income decreased slightly from \$0.6m in Q1, 2011 to \$0.5m this quarter.

Profit After Tax increased by almost 10% to \$4.1m from \$3.8m in the comparative period last year. Meanwhile, EPS for Q1, 2012 increased by 11% from 17.5 cents to 19.4 cents. The tax charge for Q1, 2012 was in line with the comparative period and represented an effective tax rate of 12.1%.

Free Cash Flows for the quarter were \$1.4m and were impacted by the timing of revenue receipts and the anticipated increased working capital associated with moving to full production of the Premier instrument. Other significant cash movements in the quarter included cash payments of \$5.6m related to the acquisition of Fiomi Diagnostics and share repurchases of \$1m. The total cash balance at the end of the quarter was \$65.5m and this will be increased by a further \$11.25m following the receipt of the final deferred consideration payment from the Stago Group on April 30, 2012.

## **Recent Developments**

- The Company continued to sell its new Premier instrument, with sales during the quarter in Europe, Turkey, South America as well as the first placements in the USA. Overall, the launch of Premier is now gathering significant momentum. Having shipped 12 instruments in Q4, 2011, this increased to 31 instruments this quarter. With the increasing pace of sales in Europe and the USA, the number of instruments sold in Q2 can be expected to increase substantially. Further increases will be achieved when Chinese registration is obtained in Q4, 2012.
- The Company announced it had obtained CE Marking and filed for FDA approval for its new point-of-care Uni-Gold™ Giardia test. This is the first of a range of new point-of-care tests to be developed at the Company's San Diego facility and will be followed by tests for C Difficile, Cryptosporidium, Syphilis, Strep pneumonia and Herpes by the end of 2012.
- The Company continued its share buyback program during the quarter, repurchasing 97,000 ADRs at a cost of \$1m.
- During the quarter Trinity completed the acquisition of Fiomi Diagnostics AB for \$13.1m. This consisted of an upfront cash payment of \$5.6m, 408,000 ADRs in Trinity Biotech and contingent consideration of \$3.4m. Fiomi is at an advanced stage of developing a point-of-care test for Troponin I and other cardiac markers. The technology, which uses a micro-pillar flow technique, is capable of providing extremely sensitive, highly reproducible, quantitative, multiplexed results which give more accurate results than the current established point-of-care tests in the \$900m cardiac market.

## ***Comments***

Commenting on the results, Kevin Tansley, Chief Financial Officer, said "This quarter we have continued our growth trajectory in terms of both revenues and earnings. Revenues grew by 7% largely driven by increased HIV revenues and sales of our new A1c analyzer, the Premier. Meanwhile, profit after tax for the quarter increased to over \$4m, thus resulting in an improvement of 11% in EPS to 19.4 cents."

Ronan O'Caomh, CEO, stated "We have had an extremely strong start to 2012. From a financial perspective we have continued to perform very well with the main highlights being the 13% growth in HIV revenues and the placement of our first Premier instruments in the USA.

During the quarter we acquired Fiomi Diagnostics AB, a Swedish company which is at an advanced stage in the development of a highly sensitive Troponin I test. This marks Trinity's entry into the highly lucrative and growing \$900m cardiac market. We expect to be selling this product in Europe in the second half of 2013 and in the USA by the end of Q2, 2014, once FDA approval has been obtained. This Troponin I test will be followed by a test for BNP and a multiplex cardiac panel, thus giving a complete suite of cardiac products. The technology also has a broad range of non-cardiac applications.

Also in the first quarter, we successfully launched the first of our new point-of-care products, a test for Giardia. This test was developed at our San Diego facility and will be followed by the launch of tests for C Difficile, Cryptosporidium, Syphilis, Strep pneumonia and Herpes by the end of the year.”

*Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties including, but not limited to, the results of research and development efforts, the effect of regulation by the United States Food and Drug Administration and other agencies, the impact of competitive products, product development commercialisation and technological difficulties, and other risks detailed in the Company's periodic reports filed with the Securities and Exchange Commission.*

Trinity Biotech develops, acquires, manufactures and markets diagnostic systems, including both reagents and instrumentation, for the point-of-care and clinical laboratory segments of the diagnostic market. The products are used to detect infectious diseases and to quantify the level of Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood. Trinity Biotech sells direct in the United States, Germany, France and the U.K. and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information please see the Company's website: [www.trinitybiotech.com](http://www.trinitybiotech.com).

**Trinity Biotech plc**  
**Consolidated Income Statements**

*(US\$000's except share data)*

|  | <b>Three Months<br/>Ended<br/>March 31,<br/>2012<br/>(unaudited)</b> | <b>Three Months<br/>Ended<br/>March 31,<br/>2011<br/>(unaudited)</b> |
|--|--|--|
| <b>Revenues</b>  | <b>20,026</b>  | <b>18,654</b>  |
| Cost of sales  | (9,683)  | (9,097)  |
| <b>Gross profit</b>  | <b>10,343</b>  | <b>9,557</b>   |
| Gross profit %   | 51.6%  | 51.2%  |
| Other operating income   | 175  | 297  |
| Research & development expenses  | (845)  | (687)  |
| Selling, general and administrative expenses                               | (5,204)  | (5,046)  |
| Indirect share based payments  | (337)  | (422)  |
| <b>Operating profit</b>  | <b>4,132</b>   | <b>3,699</b>   |
| Financial income   | 546  | 642  |
| Financial expenses   | (1)  | (4)  |
| <b>Net financing income</b>  | <b>545</b>   | <b>638</b>   |
| <b>Profit before tax</b>   | <b>4,677</b>   | <b>4,337</b>   |
| Income tax expense   | (567)  | (585)  |
| <b>Profit for the period</b>   | <b>4,110</b>   | <b>3,752</b>   |
| Earnings per ADR (US cents)  | 19.4   | 17.5   |
| Diluted earnings per ADR (US cents)  | 18.6   | 16.9   |
| Weighted average no. of ADRs used in<br>computing basic earnings per ADR   | 21,217,683   | 21,388,026   |
| Weighted average no. of ADRs used in<br>computing diluted earnings per ADR | 22,154,641   | 22,191,689   |

*The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company's accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).*

**Trinity Biotech plc**  
**Consolidated Balance Sheets**

|  | <b>March 31,</b><br><b>2012</b><br><b>US\$ '000</b><br><b>(unaudited)</b> | <b>Dec 31,</b><br><b>2011</b><br><b>US\$ '000</b><br><b>(audited)</b> |
|--|---|---|
| <b>ASSETS</b>  |   |   |
| <b>Non-current assets</b>                                      |   |   |
| Property, plant and equipment                                  | 7,823   | 7,626   |
| Goodwill and intangible assets                                 | 59,832  | 45,390  |
| Deferred tax assets  | 3,034   | 2,977   |
| Other assets   | 528   | 493   |
| <b>Total non-current assets</b>                                | 71,217  | 56,486  |
| <b>Current assets</b>  |   |   |
| Inventories  | 19,301  | 19,838  |
| Trade and other receivables                                    | 25,677  | 23,973  |
| Income tax receivable  | 271   | 117   |
| Cash and cash equivalents                                      | 65,499  | 71,085  |
| <b>Total current assets</b>                                    | 110,748   | 115,013   |
| <b>TOTAL ASSETS</b>  | 181,965   | 171,499   |
| <b>EQUITY AND LIABILITIES</b>                                  |   |   |
| <b>Equity attributable to the equity holders of the parent</b> |   |   |
| Share capital  | 1,109   | 1,106   |
| Share premium  | 3,086   | 2,736   |
| Accumulated surplus  | 151,082   | 143,482   |
| Other reserves   | 4,021   | 4,008   |
| <b>Total equity</b>  | 159,298   | 151,332   |
| <b>Current liabilities</b>                                     |   |   |
| Interest-bearing loans and borrowings                          | 70  | 108   |
| Income tax payable   | 1,879   | 1,582   |
| Trade and other payables                                       | 10,104  | 11,589  |
| Provisions   | 50  | 50  |
| <b>Total current liabilities</b>                               | 12,103  | 13,329  |
| <b>Non-current liabilities</b>                                 |   |   |
| Other payables   | 3,273   | 10  |
| Deferred tax liabilities                                       | 7,291   | 6,828   |
| <b>Total non-current liabilities</b>                           | 10,564  | 6,838   |
| <b>TOTAL LIABILITIES</b>                                       | 22,667  | 20,167  |
| <b>TOTAL EQUITY AND LIABILITIES</b>                            | 181,965   | 171,499   |

*The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company's accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).*

**Trinity Biotech plc**  
**Consolidated Statement of Cash Flows**

| <i>(US\$000's)</i>                                      | <b>Three Months<br/>Ended<br/>March 31,<br/>2012<br/>(unaudited)</b> | <b>Three Months<br/>Ended<br/>March 31,<br/>2011<br/>(unaudited)</b> |
|---|--|--|
| <b>Cash and cash equivalents at beginning of period</b> | <b>71,085</b>  | <b>58,002</b>  |
| Operating cash flows before changes in working capital  | 5,115  | 4,773  |
| Changes in working capital                              | (1,821)  | 980  |
| Cash generated from operations                          | <u>3,294</u>   | <u>5,753</u>   |
| Net Interest and Income taxes received                  | 475  | 238  |
| Capital Expenditure & Financing (net)                   | (2,387)  | (2,105)  |
| Free cash flow  | <u>1,382</u>   | <u>3,886</u>   |
| Cash paid to acquire Phoenix Bio-tech                   | (333)  | (1,000)  |
| Cash paid to acquire Fiom Diagnostics                   | (5,624)  | -  |
| Repurchase of own company shares                        | (1,011)  | (1,070)  |
| <b>Cash and cash equivalents at end of period</b>       | <u><b>65,499</b></u>   | <u><b>59,818</b></u>   |

*The above financial statements have been prepared in accordance with the principles of International Financial Reporting Standards and the Company's accounting policies but do not constitute an interim financial report as defined in IAS 34 (Interim Financial Reporting).*